Evaluation of Ablation Index and VISITAG™ (ABI-173)

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 340 participants.

Also called NCT03062046

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 340 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03062046
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Austria, Belgium, Denmark, France, Ireland, Italy, Netherlands, Switzerland, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03062046. Allocation not applicable; no masking; primary purpose treatment. Start 2017-01-27 (actual); primary completion 2019-03-27 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluation of Ablation Index and VISITAG™ (ABI-173)
Acronym
VISTAX
Condition
Paroxysmal Atrial Fibrillation
Intervention (Device)
RF ablation
Lead sponsor
Biosense Webster, Inc. (class: industry)

Record details

Record id
cardio:ct-nct03062046
Content hash
0ee4533e35d6aff1369b025a2b5d93bbaaf9dd24a7e5aabc37aadd2026c87477